Skip to main content

Table 2 Treatment and outcomes of patients with giant-cell arteritis over 80 years old who received tocilizumab

From: Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis

Characteristics

Patients (n = 21)

Total follow-up, in months

20 [3–48]

Antiplatelets

18 (86)

Glucocorticoid use

 Initial dose, mg/kg

0.8 [0.6–1.1]

 Duration of intake in all patientsa, in months

14 [2–48]

 Number of patients who stopped GCs after TCZ introduction

14 (67)

 Delay to stop GCs after TCZ introduction

8 [2–21]

Tocilizumab use

 Introduction at GCA diagnosis

6 (29)

 Introduction during the FU

15 (71)

 Delay of introduction in patients with TCZ introduction at FU

8 [3–37]

 First-line immunosuppressant

17 (81)

 Second-line immunosuppressant

4 (19)

 Number of patients who discontinued TCZ at last FU

11 (52)

 Duration of TCZ use in all patients, in months

7 [3–28]

 Duration of TCZ in patients who stopped it, in months

8 [3–28]

Number of patients with a control of large-vessel imaging

3

 Improvement

2

 No improvement

1

Relapses before and after TCZ introduction

 Number of patients who relapsed

11 (52)

 Total number of relapses

19

 Delay of the first relapse, in months

5 [2–19]

 Number of relapses before TCZ

15

 Under TCZ

2

 After TCZ discontinuation

2

 Delay of relapse after TCZ discontinuation, in months

1 and 13

Death

4 (19)

  1. Values are numbers (%) or medians [range]. GCs, glucocorticoids; FU, follow-up; TCZ, tocilizumab
  2. aFrom GC introduction to stop or to the last follow-up visit if GCs are ongoing